Serum neopterin as an objective marker of psoriatic disease activity

Acta Dermato-Venereologica

Volumn 80, Issue 3, 2000, Pages 185-187

  Sanchez Regana, M ^a   Catasus, M ^a   Creus, L ^a   Umbert, P ^a  

^a HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

Author keywords

Neopterin; Psoriasis; Psoriatic activity

Indexed keywords

COAL TAR; CREATININE; NEOPTERIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HELPER CELL; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; RADIOIMMUNOASSAY; URINE LEVEL;

EID: 0033811174     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155500750042934     Document Type: Article

References (31)

1. Noninvasive bioengineering assessment of psoriasis
2. Severe psoriasis - Oral therapy with a new retinoid
3. On the limitations of the psoriasis area and severity index (PASI)
4. Production of pteridines during hematopoiesis and T-lymphocyte proliferation: Potencial participation in the control of cytokine signal transmission
5. Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamma
6. Neopterin release from human endothelial cells is triggered by interferon-gamma
7. Different lymphoid cell populations produce varied levels of neopterin, beta 2-micro-glogulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha
8. Cytokine induction of neopterin production
9. Contrasting effects of interferon-gamma and interleukin-4 on neopterin generation from human adherent monocytes
10. Neopterin as an endogenous antioxidant
11. The role of neopterin as a monitor of cellular immune activation on transplantation, inflammatory, infectious, and malignant diseases
12. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis
13. Urinary neopterin in patients with systemic lupus erythematosus
14. Serum neopterin levels in patients with hepatocellular carcinoma
15. Neopterin and prognosis in patients with adenocarcinoma of the colon
16. Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome (AIDS)
17. Serum neopterin after lung transplantation
18. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases
19. Biliary and urinary neopterin concentrations in monitoring liver-allograf recipients
20. Treatment of psoriasis
21. Immune activation and psoriasis
22. Neopterin and psoriasis
23. Cyclosporin A in psoriasis: Monitoring by neopterin concentrations in serum and urine
24. Neopterin, immune activation, and psoriasis
25. Increased urine neopterin levels in psoriasis
26. Urine neopterin concentrations and activity of psoriasis (Correspondence)
27. Quantitative determination of pterins in biological fluids by high-performance liquid chromatography
28. Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamma
29. Epidermal T lymphocytes and HLA-DR expression in psoriasis
30. T cells involved in psoriasis vulgaris belong to the Th1 subset
31. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: A comparison of sIL-2R, sCD27, sCD4, sCD8 and ICAM-1